Integrated Advisors Network LLC Buys 2,148 Shares of The Clorox Company (NYSE:CLX)

Integrated Advisors Network LLC boosted its position in shares of The Clorox Company (NYSE:CLX - Free Report) by 98.1% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,338 shares of the company's stock after purchasing an additional 2,148 shares during the period. Integrated Advisors Network LLC's holdings in Clorox were worth $639,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the company. Norges Bank bought a new position in shares of Clorox in the 4th quarter valued at about $259,041,000. FMR LLC lifted its position in Clorox by 75.4% during the fourth quarter. FMR LLC now owns 1,361,758 shares of the company's stock worth $221,163,000 after acquiring an additional 585,526 shares during the last quarter. Marshall Wace LLP lifted its position in Clorox by 549.8% during the fourth quarter. Marshall Wace LLP now owns 542,726 shares of the company's stock worth $88,144,000 after acquiring an additional 459,203 shares during the last quarter. ExodusPoint Capital Management LP lifted its position in Clorox by 187.9% during the fourth quarter. ExodusPoint Capital Management LP now owns 698,900 shares of the company's stock worth $113,508,000 after acquiring an additional 456,114 shares during the last quarter. Finally, Man Group plc lifted its position in Clorox by 154.6% during the fourth quarter. Man Group plc now owns 570,503 shares of the company's stock worth $92,655,000 after acquiring an additional 346,449 shares during the last quarter. Institutional investors own 78.53% of the company's stock.

Insider Buying and Selling

In other Clorox news, Director Pierre R. Breber bought 4,000 shares of the stock in a transaction that occurred on Wednesday, May 7th. The shares were bought at an average price of $136.57 per share, for a total transaction of $546,280.00. Following the acquisition, the director now directly owns 4,000 shares of the company's stock, valued at approximately $546,280. The trade was a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.57% of the stock is currently owned by company insiders.

Clorox Trading Down 3.3%

CLX stock traded down $4.25 during midday trading on Friday, hitting $123.03. The stock had a trading volume of 1,709,082 shares, compared to its average volume of 1,361,693. The business has a fifty day moving average price of $134.91 and a two-hundred day moving average price of $148.35. The Clorox Company has a 1-year low of $122.84 and a 1-year high of $171.37. The company has a current ratio of 0.94, a quick ratio of 0.60 and a debt-to-equity ratio of 20.52. The firm has a market cap of $15.16 billion, a P/E ratio of 33.61, a price-to-earnings-growth ratio of 2.62 and a beta of 0.54.

Clorox (NYSE:CLX - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported $1.45 earnings per share for the quarter, missing analysts' consensus estimates of $1.57 by ($0.12). Clorox had a return on equity of 316.87% and a net margin of 6.38%. The business had revenue of $1.67 billion during the quarter, compared to analyst estimates of $1.74 billion. During the same quarter in the prior year, the company earned $1.71 EPS. The company's revenue was down 8.0% on a year-over-year basis. On average, sell-side analysts predict that The Clorox Company will post 7.15 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

CLX has been the topic of several recent research reports. JPMorgan Chase & Co. lowered their target price on shares of Clorox from $151.00 to $144.00 and set a "neutral" rating on the stock in a report on Tuesday, May 6th. Evercore ISI set a $140.00 price objective on shares of Clorox and gave the company an "underperform" rating in a research note on Tuesday, May 6th. Barclays decreased their price objective on shares of Clorox from $134.00 to $129.00 and set an "underweight" rating on the stock in a research note on Wednesday, May 7th. Wells Fargo & Company decreased their price objective on shares of Clorox from $145.00 to $142.00 and set an "equal weight" rating on the stock in a research note on Tuesday, May 6th. Finally, Morgan Stanley decreased their price objective on shares of Clorox from $165.00 to $150.00 and set an "equal weight" rating on the stock in a research note on Tuesday, May 6th. Three equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and one has given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $151.23.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.